Stockscreener 앱 받기
0.615
6.02%
0.0349
전일 마감가:
$0.5801
열려 있는:
$0.6109
하루 거래량:
7.97M
Relative Volume:
7.48
시가총액:
$79.44M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-2.7955
EPS:
-0.22
순현금흐름:
$-19.57M
1주 성능:
-4.67%
1개월 성능:
-15.14%
6개월 성능:
-31.02%
1년 성능:
-27.36%
1일 변동 폭
$0.59
$0.6358
1주일 범위
$0.5708
$0.6675
52주 변동 폭
$0.551
$1.29
Atossa Therapeutics Inc Stock (ATOS) Company Profile
명칭
Atossa Therapeutics Inc
전화
206.588.0256
주소
10202 5TH AVENUE NE, SEATTLE, WA
ATOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.615 | 74.93M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-01-26 | 개시 | Maxim Group | Buy |
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics (ATOS) Gains as FDA Grants Orphan Drug Statu - GuruFocus
ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy - Intellectia AI
Experimental DMD treatment from Atossa earns rare FDA orphan status - Stock Titan
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10% - Intellectia AI
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13% - Intellectia AI
Why Did ATOS Stock Jump 10% In Pre-Market Today? - Asianet Newsable
FDA Grants Orphan Drug Status to Atossa Therapeutics' (ATOS) Z-E - GuruFocus
What Wall Street predicts for Atossa Therapeutics Inc stock priceAnalyst Upgrade & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Atossa Therapeutics targets breast cancer care breakthroughs - Traders Union
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - Улправда
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - Улправда
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - Улправда
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - Улправда
Bearish Setup: Will Atossa Therapeutics Inc. stock maintain growth storyJuly 2025 Decliners & High Accuracy Investment Entry Signals - Улправда
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study By Investing.com - Investing.com India
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for - GuruFocus
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial - TipRanks
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study - Investing.com
Atossa Therapeutics Receives FDA Approval for Metastatic Breast Cancer Study - TradingView — Track All Markets
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer - Fidelity
Reviewing Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) - Defense World
Seattle InnoDiagrid emerges from stealth I Atossa troubles - The Business Journals
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average – Should You Sell? - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Norwich Bulletin
Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey - Defense World
Will Atossa Therapeutics Inc. stock outperform international peersChart Signals & Community Consensus Trade Alerts - Улправда
Earnings Report: Is Atossa Therapeutics Inc. stock a buy before product launchesTake Profit & Smart Money Movement Tracker - Улправда
Atossa Therapeutics Earnings Notes - Trefis
Will Atossa Therapeutics Inc. stock maintain growth storyBond Market & Free AI Powered Buy and Sell Recommendations - DonanımHaber
Will Atossa Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Technical Pattern Based Signals - Улправда
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category - BioSpace
Atossa Therapeutics Wins R&D Excellence Award for Precision Endocrine Therapy Innovation - Clinical Trials Arena
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Atossa Therapeutics (ATOS) Highlights Promising (Z)-endoxifen Tr - GuruFocus
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium - WV News
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium | ATOS Stock News - Longbridge
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
Atossa gains on rare pediatric disease status for Duchenne asset - MSN
Atossa Therapeutics Inc (ATOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Atossa Therapeutics Inc 주식 (ATOS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
4.73%
0.92%
자본화:
|
볼륨(24시간):